Adam M Hill

Adam is a highly experienced leader in the life sciences with a career developed at the interface of Industry, Academia and Health systems. A dual-qualified Clinician and Mechanical Engineer, Adam is excited about the interface of healthcare and technology.

Adam is a leader in the Life Sciences industry with a career developed at the interface of Industry, Academia and Health systems. Most recently, Adam led a public listed diagnostics company (Oncimmune) through a tricky turnaround, and transition from the founding team. As CEO of Oncimmune plc, Adam led the redevelopment of the strategy and delivered a turnaround transformation. Concurrently, he is a visiting Professor at Imperial College London, an independent NED of Imperial College Health Partners, Vice-Chair of the Association of British HealthTech Industries. Previously, Adam was Chief Strategy Officer and an Executive Director of McLaren Applied Technologies focused on applying the company’s deep technical expertise to developing high growth businesses, including a Health Technology programme.Adam is a dual-qualified Clinician and Mechanical Engineer, graduating from Imperial College London as a Medical Doctor, whilst also earning a PhD in Engineering; following his academic education, Adam attended Imperial College Business School, and the Royal Military Academy Sandhurst. He received his postgraduate clinical training in General and Orthopaedic Surgery from the Royal College of Surgeons of England; and, Chartered engineering qualification from the Institution of Mechanical Engineers.

Current board positions are CEO of Oncimmune; Association of British HealthTech Industries (ABHI – Vice-Chair and Non-Executive Director Board Member); Imperial College Health Partners (ICHP); MyRecovery.ai and Accelerated Clinical Trials (ACT).